Skin & cosmetic
Tripeptide-1
Palmitoyl Tripeptide-5, TGF-beta mimetic peptide
Tripeptide-1 and its palmitoylated form are cosmetic peptides marketed for collagen support, proposed to work by activating latent transforming growth factor beta already present in skin.
Also known as: Palmitoyl Tripeptide-5, Syn-Coll, tripeptide 1
- Status
- Tripeptide-1 is used as a cosmetic or over-the-counter ingredient, not as an approved drug.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Not applicable — acts locally in skin.
- How it's taken
- Topical, in a leave-on serum or cream
- Mechanism
- Cosmetic / topical
- Pathways
- Collagen Synthesis
How Tripeptide-1 works
Rather than signalling collagen synthesis directly, this peptide is proposed to mimic thrombospondin-1, the endogenous activator of latent TGF-beta. Skin contains substantial latent TGF-beta; freeing it would drive fibroblast collagen production through an established pathway. The proposed mechanism is therefore indirect — recruiting an existing reservoir rather than supplying a new signal.
What research has looked at
- The mechanism is conceptually distinct from the GHK-derived peptides, targeting activation of an existing growth factor pool rather than direct fibroblast signalling.
- TGF-beta is unambiguously a master regulator of collagen synthesis, so the pathway itself is not speculative.
- Palmitoylation improves penetration relative to the unmodified peptide.
- It is well tolerated and non-irritating.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Supporting data are manufacturer-generated, small and short-duration, with little independent replication.
- Skin penetration remains the unresolved question for all topical peptides, and formulation matters more than the peptide identity.
- TGF-beta is also the central mediator of fibrosis and scarring; a peptide that activates it is not obviously benign with chronic use, and long-term data do not exist.
- Visible effects are modest and require months of consistent application.
- It is a cosmetic ingredient, not a drug, and is not evaluated by the FDA for efficacy.
Sources
- PubMed research on tripeptide-1 TGF-beta thrombospondin cosmetic · NIH · National Library of Medicine
- DrugBank record for palmitoyl tripeptide-5 · DrugBank
- Active clinical trials for palmitoyl tripeptide-5 · U.S. National Library of Medicine
Track Tripeptide-1 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Tripeptide-1 FAQ
What is Tripeptide-1?
Tripeptide-1 and its palmitoylated form are cosmetic peptides marketed for collagen support, proposed to work by activating latent transforming growth factor beta already present in skin.
How does Tripeptide-1 work?
Rather than signalling collagen synthesis directly, this peptide is proposed to mimic thrombospondin-1, the endogenous activator of latent TGF-beta. Skin contains substantial latent TGF-beta; freeing it would drive fibroblast collagen production through an established pathway. The proposed mechanism is therefore indirect — recruiting an existing reservoir rather than supplying a new signal.
Is Tripeptide-1 FDA approved?
No. Tripeptide-1 is used as a cosmetic or over-the-counter ingredient, not as an approved drug. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Tripeptide-1?
Reported half-life: Not applicable — acts locally in skin.
How is Tripeptide-1 taken?
Topical, in a leave-on serum or cream.
What side effects have been reported with Tripeptide-1?
Reported in the sources: Supporting data are manufacturer-generated, small and short-duration, with little independent replication; Skin penetration remains the unresolved question for all topical peptides, and formulation matters more than the peptide identity; TGF-beta is also the central mediator of fibrosis and scarring; a peptide that activates it is not obviously benign with chronic use, and long-term data do not exist; Visible effects are modest and require months of consistent application; It is a cosmetic ingredient, not a drug, and is not evaluated by the FDA for efficacy.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.